MAZE:NASDAQMaze Therapeutics, Inc. Analysis

Maze Therapeutics is trading at $26.85, well below its 20‑day ($33.82), 50‑day ($41.70) and 200‑day ($31.32) simple moving averages, and the RSI of 25.7 signals an oversold condition. Technical indicators such as a bearish MACD (-4.82 vs signal -4.57) and a recent decline in volume suggest short‑term weakness, while the current price hovers just above the identified support level of $26.16. Insider activity adds a red flag: the company’s president and another executive sold a combined $736k of shares less than a month before the upcoming earnings release. At the same time, the stock exhibits extreme volatility (136% 30‑day) and a high beta (~0.95), reflecting heightened market sensitivity.
On the upside, the firm announced promising Phase 2 “HORIZON” data for MZE829, its lead APOL1 inhibitor, and analysts (11 in total) have issued a “strong buy” with a median target of $58, implying a potential upside of over 100%. The balance sheet shows $342 M in cash against $23 M of debt, providing a solid runway despite negative EBITDA and cash‑flow burn. While the valuation appears stretched given the lack of revenue and negative earnings, the combination of a high‑growth pipeline, strong cash position, and substantial upside potential supports a longer‑term bullish view, albeit with considerable risk.